Physiogenex will be presenting an e-Poster at the 31st conference of the Asian Pacific Association for the Study of Liver (APASL) to be held in Seoul, Korea and virtually on March 30th – April 3rd 2022.
The presentation title is “SEMAGLUTIDE AND PIOGLITAZONE IMPROVE CARDIOMETABOLIC PARAMETERS IN DIET-INDUCED OBESE NASH HAMSTERS”
The conference attendees will be able to access the e-Poster during the whole conference period, within the e-Poster zone or virtually (search for poster# OP-0466) through the online platform .
Feel free to contact us if you wish to set-up an appointment with the poster presenter Dr. François Briand, Director of Research and Business Development at Physiogenex, and/or discuss your drug development projects with us.
About us
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.